PTC Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . PTC Therapeutics
PTCT Stock  USD 76.70  0.06  0.08%   
Analyzing historical trends in various income statement and balance sheet accounts from PTC Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting PTC Therapeutics' valuation are summarized below:
Gross Profit
1.3 B
Profit Margin
0.4225
Market Capitalization
6.2 B
Enterprise Value Revenue
2.7454
Revenue
1.8 B
There are currently one hundred twenty fundamental measures for PTC Therapeutics that can be evaluated and compared over time across peers in the sector. All traders should check out PTC Therapeutics' latest fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 3.3 B in 2026. Enterprise Value is likely to gain to about 4.9 B in 2026

PTC Therapeutics Total Revenue

974.19 Million

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 201.6 M, Total Revenue of 974.2 M or Research Development of 645.4 M, as well as many indicators such as Price To Sales Ratio of 4.7, Dividend Yield of 0.0 or Days Sales Outstanding of 52.14. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with PTC Stock
Check out the analysis of PTC Therapeutics Correlation against competitors.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

PTC Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.1 B2 B1 B
Slightly volatile
Other Current Liabilities340.9 M324.7 M138.4 M
Slightly volatile
Total Current Liabilities701.5 M668.1 M261.6 M
Slightly volatile
Other Liabilities263.2 M309.9 M262.5 M
Slightly volatile
Accounts Payable10.5 M19.9 M10.7 M
Slightly volatile
Cash941.5 M896.7 M360 M
Slightly volatile
Other Assets40.3 M38.4 M18.1 M
Slightly volatile
Short Term Investments289.8 M414 M271.7 M
Slightly volatile
Total Liabilities3.4 B3.2 B1.2 B
Slightly volatile
Property Plant Equipment87.7 M83.5 M38.3 M
Slightly volatile
Short and Long Term Debt Total3 B2.8 B828.1 M
Slightly volatile
Property Plant And Equipment Net142.1 M135.3 M65.6 M
Slightly volatile
Current Deferred Revenue6 M6.3 M22 M
Very volatile
Non Current Assets Total472.3 M390.4 M405 M
Slightly volatile
Non Currrent Assets Other32.9 M23.8 M28 M
Slightly volatile
Cash And Short Term Investments1.4 B1.3 B540.3 M
Slightly volatile
Net Receivables191.5 M182.3 M72.8 M
Slightly volatile
Common Stock Total Equity45.3 K82.8 K45.1 K
Slightly volatile
Common Stock Shares Outstanding52.2 M88.4 M48.7 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B2 B991.4 M
Slightly volatile
Non Current Liabilities Total2.7 B2.6 B945 M
Slightly volatile
Property Plant And Equipment Gross182.3 M173.7 M78.2 M
Slightly volatile
Total Current Assets1.6 B1.6 B647.5 M
Slightly volatile
Short Term Debt327.5 M311.9 M100.9 M
Slightly volatile
Common Stock50.8 K88.5 K46.2 K
Slightly volatile
Capital Surpluse1.6 B2.7 B1.4 B
Slightly volatile
Non Current Liabilities Other23.4 M24.6 M222 M
Slightly volatile
Long Term Debt Total690.4 M657.5 M288.2 M
Slightly volatile
Short and Long Term Debt311.3 M296.5 M132.8 M
Slightly volatile
Net Invested Capital785.2 M1.5 B592.1 M
Slightly volatile
Net Working Capital543.3 M902.2 M386.2 M
Slightly volatile
Capital Stock75.1 K88.5 K61.7 K
Slightly volatile
Capital Lease Obligations128 M119.5 M114.2 M
Slightly volatile

PTC Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue974.2 M927.8 M372.6 M
Slightly volatile
Research Development645.4 M614.7 M304.5 M
Slightly volatile
Depreciation And Amortization50.4 M87 M46 M
Slightly volatile
Selling General Administrative175.8 M346 M163.3 M
Slightly volatile
Other Operating Expenses1.3 B1.3 B585.4 M
Slightly volatile
Total Operating Expenses1.3 B1.2 B562.8 M
Slightly volatile
Interest Income10.5 M14.4 M8.6 M
Slightly volatile
Reconciled Depreciation80.1 M87 M51.4 M
Slightly volatile
Non Recurring26.7 M30 M32.8 M
Slightly volatile

PTC Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures89.7 M85.4 M43.5 M
Slightly volatile
End Period Cash Flow960.3 M914.6 M282.8 M
Slightly volatile
Stock Based Compensation54.8 M85.8 M49.5 M
Slightly volatile
Begin Period Cash Flow736.9 M701.8 M212.1 M
Slightly volatile
Depreciation53.6 M87 M48.6 M
Slightly volatile
Other Non Cash Items46.4 M67.5 M41.5 M
Slightly volatile
Sale Purchase Of Stock89.2 M64 M116.9 M
Slightly volatile
Change To Netincome79 M130.8 M70.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.74.9410.5613
Pretty Stable
Days Sales Outstanding52.1464.5660.8063
Slightly volatile
Average Payables2.1 M2.4 M2.6 M
Slightly volatile
Stock Based Compensation To Revenue0.10.110.2348
Pretty Stable
Capex To Depreciation0.620.880.7328
Slightly volatile
EV To Sales11.997.3610.2478
Pretty Stable
Inventory Turnover1.152.231.054
Slightly volatile
Days Of Inventory On Hand161170545
Slightly volatile
Sales General And Administrative To Revenue0.80.520.7648
Pretty Stable
Research And Ddevelopement To Revenue1.470.761.2729
Slightly volatile
Capex To Revenue0.07430.08280.0859
Slightly volatile
Cash Per Share6.9413.358.4632
Slightly volatile
Intangibles To Total Assets0.130.140.3398
Slightly volatile
Current Ratio4.382.73.738
Pretty Stable
Receivables Turnover5.565.8516.6676
Slightly volatile
Capex Per Share0.470.870.5688
Slightly volatile
Average Receivables1.2 M1.1 M1 M
Very volatile
Revenue Per Share9.929.456.1231
Slightly volatile
Interest Debt Per Share32.4430.911.7403
Slightly volatile
Debt To Assets1.371.30.5581
Slightly volatile
Operating Cycle220197251
Slightly volatile
Ebt Per Ebit0.91.081.1041
Slightly volatile
Quick Ratio4.332.663.7003
Pretty Stable
Net Income Per E B T1.11.151.0171
Pretty Stable
Cash Ratio2.591.542.2129
Pretty Stable
Days Of Inventory Outstanding161170545
Slightly volatile
Days Of Sales Outstanding52.1464.5660.8063
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.021.521.2668
Slightly volatile
Fixed Asset Turnover8.757.898.0628
Very volatile
Debt Ratio1.371.30.5581
Slightly volatile
Price Sales Ratio4.74.9410.5613
Pretty Stable
Asset Turnover0.620.540.6633
Slightly volatile

PTC Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.3 B3.1 B1.8 B
Slightly volatile
Enterprise Value4.9 B4.6 B2.3 B
Slightly volatile

PTC Fundamental Market Drivers

Forward Price Earnings6.006
Cash And Short Term Investments1.1 B

PTC Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6.3 M6 M
Total Revenue927.8 M974.2 M
Cost Of Revenue51.7 M37.1 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.52  0.80 
Research And Ddevelopement To Revenue 0.76  1.47 
Capex To Revenue 0.08  0.07 
Revenue Per Share 9.45  9.92 
Ebit Per Revenue(0.34)(0.35)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY